156 related articles for article (PubMed ID: 19900844)
1. IFNbeta-1a therapy for multiple sclerosis expands regulatory CD8+ T cells and decreases memory CD8+ subset: a longitudinal 1-year study.
Aristimuño C; de Andrés C; Bartolomé M; de las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
Clin Immunol; 2010 Feb; 134(2):148-57. PubMed ID: 19900844
[TBL] [Abstract][Full Text] [Related]
2. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis.
de Andrés C; Aristimuño C; de Las Heras V; Martínez-Ginés ML; Bartolomé M; Arroyo R; Navarro J; Giménez-Roldán S; Fernández-Cruz E; Sánchez-Ramón S
J Neuroimmunol; 2007 Jan; 182(1-2):204-11. PubMed ID: 17157927
[TBL] [Abstract][Full Text] [Related]
3. Clinical response to interferon-beta-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells Differential role of circulating dendritic cells and CD4+ regulatory T-cells in relapsing-remitting multiple sclerosis: a 1-year longitudinal study.
de Andrés C; Aristimuño C; Bartolomé M; de Las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
J Neuroimmunol; 2009 Jul; 212(1-2):112-20. PubMed ID: 19446889
[TBL] [Abstract][Full Text] [Related]
4. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
5. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
[TBL] [Abstract][Full Text] [Related]
6. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
[TBL] [Abstract][Full Text] [Related]
7. Increased CD8+ central memory T cells in patients with multiple sclerosis.
Liu GZ; Fang LB; Hjelmström P; Gao XG
Mult Scler; 2007 Mar; 13(2):149-55. PubMed ID: 17439879
[TBL] [Abstract][Full Text] [Related]
8. CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients.
Frisullo G; Nociti V; Iorio R; Plantone D; Patanella AK; Tonali PA; Batocchi AP
Hum Immunol; 2010 May; 71(5):437-41. PubMed ID: 20138197
[TBL] [Abstract][Full Text] [Related]
9. Numerical defects in CD8+CD28- T-suppressor lymphocyte population in patients with type 1 diabetes mellitus and multiple sclerosis.
Mikulkova Z; Praksova P; Stourac P; Bednarik J; Strajtova L; Pacasova R; Belobradkova J; Dite P; Michalek J
Cell Immunol; 2010; 262(2):75-9. PubMed ID: 20219185
[TBL] [Abstract][Full Text] [Related]
10. Migration of T-cell subsets in multiple sclerosis and the effect of interferon-beta1a.
Dressel A; Mirowska-Guzel D; Gerlach C; Weber F
Acta Neurol Scand; 2007 Sep; 116(3):164-8. PubMed ID: 17714329
[TBL] [Abstract][Full Text] [Related]
11. Increase of CD8+ T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls.
Haegele KF; Stueckle CA; Malin JP; Sindern E
J Neuroimmunol; 2007 Feb; 183(1-2):168-74. PubMed ID: 17084910
[TBL] [Abstract][Full Text] [Related]
12. Expansion of regulatory CD8+ T-lymphocytes and fall of activated CD8+ T-lymphocytes after i.v. methyl-prednisolone for multiple sclerosis relapse.
Aristimuño C; Navarro J; de Andrés C; Martínez-Ginés L; Giménez-Roldán S; Fernández-Cruz E; Sánchez-Ramón S
J Neuroimmunol; 2008 Nov; 204(1-2):131-5. PubMed ID: 18835045
[TBL] [Abstract][Full Text] [Related]
13. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis.
Zafranskaya M; Oschmann P; Engel R; Weishaupt A; van Noort JM; Jomaa H; Eberl M
Immunology; 2007 May; 121(1):29-39. PubMed ID: 17239199
[TBL] [Abstract][Full Text] [Related]
14. Memory and naïve B-cell subsets in patients with multiple sclerosis.
Niino M; Hirotani M; Miyazaki Y; Sasaki H
Neurosci Lett; 2009 Oct; 464(1):74-8. PubMed ID: 19666086
[TBL] [Abstract][Full Text] [Related]
15. CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment.
Frisullo G; Iorio R; Plantone D; Marti A; Nociti V; Patanella AK; Batocchi AP
Mult Scler; 2011 May; 17(5):556-66. PubMed ID: 21177324
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy.
Chiarini M; Serana F; Zanotti C; Capra R; Rasia S; Rottoli M; Rovaris M; Caputo D; Cavaletti G; Frigo M; Frigeni B; Clerici R; Rezzonico M; Caimi L; Imberti L
Mult Scler; 2012 Jun; 18(6):788-98. PubMed ID: 22086901
[TBL] [Abstract][Full Text] [Related]
17. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.
Mei FJ; Osoegawa M; Ochi H; Minohara M; Nan S; Murai H; Ishizu T; Taniwaki T; Kira J
J Neurol Sci; 2006 Jul; 246(1-2):71-7. PubMed ID: 16581087
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
[TBL] [Abstract][Full Text] [Related]
19. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
Perini P; Calabrese M; Biasi G; Gallo P
J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
[TBL] [Abstract][Full Text] [Related]
20. CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis.
Krakauer M; Sorensen PS; Sellebjerg F
J Neuroimmunol; 2006 Dec; 181(1-2):157-64. PubMed ID: 17081623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
